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ABSTRACT
Introduction: Self-management of hypertension,
including self-monitoring and antihypertensive
medication titration, lowers blood pressure (BP) at
1 year compared to usual care. The aim of the current
trial is to assess the effectiveness of the Home and
Online Management and Evaluation of Blood Pressure
(HOME BP) intervention for the self-management of
hypertension in primary care.
Methods and analysis: The HOME BP trial will be a
randomised controlled trial comparing BP self-
management—consisting of the HOME BP online
digital intervention with self-monitoring, lifestyle advice
and antihypertensive drug titration—with usual care for
people with uncontrolled essential hypertension.
Eligible patients will be recruited from primary care and
randomised to usual care or to self-management using
HOME BP. The primary outcome will be the difference
in mean systolic BP (mm Hg) at 12-month follow-up
between the intervention and control groups adjusting
for baseline BP and covariates. Secondary outcomes
(also adjusted for baseline and covariates where
appropriate) will be differences in mean BP at
6 months and diastolic BP at 12 months; patient
enablement; quality of life, and economic analyses
including all key resources associated with the
intervention and related services, adopting a broad
societal perspective to include NHS, social care and
patient costs, considered within trial and modelled with
a lifetime horizon. Medication beliefs, adherence and
changes; self-efficacy; perceived side effects and
lifestyle changes will be measured for process
analyses. Qualitative analyses will explore patient and
healthcare professional experiences of HOME BP to
gain insights into the factors affecting acceptability,
feasibility and adherence.
Ethics and dissemination: This study has received
NHS ethical approval (REC reference 15/SC/0082). The
findings from HOME BP will be disseminated widely
through peer-reviewed publications, scientific
conferences and workshops. If successful, HOME BP
will be directly applicable to UK primary care
management of hypertension.
Trial registration number: ISRCTN13790648;
pre-results.
INTRODUCTION
Blood pressure (BP) is a key risk factor for
cardiovascular disease, the largest cause of
morbidity and mortality worldwide.1 The
health survey for England (2012) identiﬁed
that ∼31% of men and 27% of women in
England have hypertension,2 yet over one-
third of all treated patients currently fail to
reach national guidelines for BP control.3
The mean BP in the UK currently ranks
among the highest in Europe (27th/35), and
the beneﬁts of a population-wide reduction
to levels seen in countries such as Denmark
and Spain (which are among the lowest)
would mean a 10 mm Hg systolic blood
pressure (SBP) reduction.4 A 10 mm Hg
Strengths and limitations of this study
▪ The study develops existing efficacious antihy-
pertensive titration procedures into an online
format.
▪ Home and Online Management and Evaluation of
Blood Pressure (HOME BP) combines medica-
tion intensification with lifestyle change and
behavioural support.
▪ The study has been designed to facilitate imple-
mentation within a primary care context.
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reduction in BP is estimated to lead to a 41% reduction
in stroke and a 22% reduction in coronary heart disease
(CHD).5 New strokes affect over 120 000 patients per
annum in the UK, and stroke is the third leading cause
of death and the most important cause of adult disabil-
ity, representing 4.4% of direct National Health Service
(NHS) costs (notwithstanding costs to social services,
patients and carers).
Factors responsible for suboptimal BP control include
those due to patients, physicians and the health system.6
The key patient factors are adherence to medication
and other health behaviours.7 8 Clinical inertia is
another key issue, whereby clinicians fail to intensify
treatment, despite evidence of inadequate control. It is
estimated that clinical inertia may account for almost
20% of the variance in BP control,9 with evidence sug-
gesting that treatment intensiﬁcation fails to occur in
nearly half (45%) of consultations in which patients had
a single BP reading above target, and around a third
(36%) with two successive readings above target.10 Lack
of intensiﬁcation may be due, in part, to the ‘white-coat
effect’, where BP readings in clinic consultations are
elevated in comparison to self-monitored home BP
readings;11 12 awareness that clinic readings may be
inaccurate may contribute to clinician and patient reluc-
tance to implement medication changes. Even with self-
monitoring of BP, clinical inertia can be profound.13
There is evidence that self-monitoring BP at home is
useful in improving medication adherence, reducing
therapeutic inertia and controlling BP,12 14–17 and
research by our team and others has shown that sus-
tained reductions in BP can indeed be achieved by
linking self-monitoring to preplanned medication titra-
tion when hypertension is uncontrolled.17–21 It can also
detect and treat masked uncontrolled hypertension.22
While some evidence suggests that aggressive titration
of antihypertensive medication without behavioural
support is optimal for controlling BP,23 further evidence
suggests that greater reductions in BP may be achieved
by the addition of behavioural support for self-
monitoring.19 24 25 This may be further facilitated when
combined with efﬁcacious lifestyle changes, such as
weight reduction, sodium restriction and increasing
physical activity,26 27 therefore HOME BP will combine
all of these components.
Rationale and risk-benefits for the current trial
Increasingly widespread access to the internet and mobile
phones28 29 means that healthcare digital interventions
(DIs) (also known as online interventions or computer-
based health interventions within the literature) are access-
ible to the majority of patients and can be used to provide
information and support at any time the patient needs it.30
DIs can empower patients by providing better access to per-
sonalised information and support for active involvement
in treatment and self-management.30 A large meta-analysis
found a small but signiﬁcant positive effect of DIs on
health-related behaviours,31 while a Cochrane review found
evidence that computer-based health interventions for
those with chronic health conditions signiﬁcantly improved
knowledge, health behaviours and clinical outcomes.32 DIs
have the potential to make signiﬁcant savings by automat-
ing routine aspects of patient education, monitoring and
support, freeing up health professional resources for when
patients most need them.33 There is accumulating evi-
dence that DIs can deliver better and more efﬁcient
healthcare in the context of hypertension,34 35 conﬁrmed
by a recent systematic review and meta-analysis undertaken
by our team.36 Therefore, the HOME BP programme has
been developed to incorporate previously identiﬁed effect-
ive intervention components (self-monitoring, preplanned
medication titrations and behavioural support) delivered
in an acceptable and feasible online format.
Study aims and research questions
The primary aim of the HOME BP trial is to assess the
feasibility, acceptability, effectiveness and cost-effectiveness
of adding the HOME BP intervention (comprising the
HOME BP online DI, self-monitoring, medication titra-
tion and lifestyle interventions with nurse support) into
primary care for the self-management of hypertension in
comparison to usual care.
Main research question:
▸ Does the HOME BP intervention to assist self-monitoring
and self-management of uncontrolled hypertension
result in greater control of SBP after 1 year?
Secondary research questions:
▸ Does the HOME BP intervention to assist self-
monitoring and self-management of uncontrolled
hypertension result in greater control of SBP and dia-
stolic blood pressure (DBP) after 6 months and DBP
after 1 year?
▸ Is the HOME BP intervention more cost-effective
than usual care in managing poorly controlled hyper-
tension in primary care?
Process analysis research questions:
▸ Which factors are related to patient engagement and
adherence to HOME BP?
▸ Which factors are related to patient medication
adherence and uptake of recommended medication
titrations?
▸ Does the inclusion of lifestyle change choices and
behavioural support result in engagement with life-
style change?
▸ Is the HOME BP intervention acceptable to patients
when integrated into routine practice?
▸ What are patient and healthcare practitioner views and
experiences of the HOME BP intervention and its add-
ition into primary care for the self-management of
poorly controlled hypertension?
METHODS AND ANALYSIS
Study design and setting
The HOME BP intervention for the self-management of
high BP consists of the integrated patient and healthcare
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practitioner HOME BP online DI, BP self-monitoring,
health professional directed and supervised titration of
antihypertensive medication and user-selected lifestyle
modiﬁcations, for people with uncontrolled essential
hypertension. The HOME BP study is a pragmatic, ran-
domised controlled trial comparing the HOME BP inter-
vention with optional nurse support to a control group
receiving usual hypertension care within a UK primary
care setting.
Study participants
Identification, follow-up and non-participation
Eligible participants will be identiﬁed from electronic
database searches of clinical systems of collaborating
general practices. Records of potentially eligible patients
will be further screened by general practitioners (GPs)
to remove participants known to meet exclusion criteria.
Remaining potentially eligible patients will be invited by
letter from the practice to attend a baseline clinic to
establish eligibility, take consent, collect baseline data
and randomise consented patients. Individuals not
wanting to take part will be provided with a form to
return should they wish to decline to take part in the
trial. This will ask for basic demographic information
and their reasons for declining, including an option not
to give a reason if they prefer not to. The practice
nurse (or other practice member as delegated by the
lead GP) will have the option to follow-up invited
patients by telephone after 1 month without response.
All patient identiﬁcation prior to consent will be con-
ducted independently of the research team to maintain
conﬁdentiality.
Eligibility criteria
Eligibility criteria will aim to capture adult patients with
treated but uncontrolled hypertension managed in
primary care who will be aged 18 or over, have a Read
code for hypertension in the clinical record (conﬁrming
hypertension), a current prescription of antihypertensive
medication and a mean BP reading (calculated from the
second and third BP readings) of >140/90 mm Hg taken
during a baseline clinic appointment. Eligible patients
will also be required to have access to the internet and
be able to comprehend the website.
Exclusion criteria
Exclusion criteria will include an inability to self-monitor
(eg, diagnosis of dementia), a mean baseline BP reading
of >180/110 mm Hg (stage 3 hypertension requiring
more urgent intervention than would be available in the
trial), hypertension not managed by family doctor (the
trial facilitates primary care titration of medication), pre-
scribed more than three antihypertensive medications
(ie, resistant hypertension), chronic kidney disease
(CKD) stage 4–5 or CKD stage 3 not managed by the
GP (likely to be under specialist care and requiring dif-
ferent BP targets), terminal disease or other condition
which in the opinion of the family doctor makes them
inappropriate to take part, pregnant or breast feeding, a
history of proteinuria (albumin creatinine Ratio (ACR)
>30 mg/mmol) (different BP targets), postural hypoten-
sion (>20 mm Hg systolic drop after 1 min standing)
(for whom intensiﬁcation of BP medication may
be inappropriate), atrial ﬁbrillation (self-monitoring
with oscillometric equipment not suitable), an acute
cardiovascular event in the previous 3 months (BP and
antihypertensive medication may not be stable) or a
household member already enrolled on the study (to
avoid bias). Participants who are involved in any other
BP research will not be able to take part in the study.
Randomisation
Participants will be randomised in a 1:1 ratio to receive
either usual care or the HOME BP intervention with
optional nurse support using the HOME BP online
system. Minimisation will be used taking into account
participants’ baseline SBP, age, diabetes status and prac-
tice. Patients are randomised to the optimal group 80%
of the time. Any random numbers the minimisation
routine might need will be computer generated, there-
fore bypassing study team involvement.
Participant flow through the study
At baseline, all patients will receive a consultation where
informed consent will be taken, as well as clinical mea-
sures (conﬁrmation of raised BP, height, weight) and
medical history. Hypoglycaemic episodes in the last
6 months will be recorded for diabetic patients. BP will
be measured after 5 min rest with a validated electronic
automated sphygmomanometer (BP TRU BPM 200).
Participants will be seated, and BP will be measured in
their left arm unless there is a reason not to (principally
lymphoedema or other medical condition). Six BP read-
ings will be taken at intervals of 1 min, with the mean of
the second and third readings used for the primary
outcome. Patients will complete demographic measures
and baseline assessments at home via HOME BP online,
following which automatic allocation to intervention or
usual care group will be triggered. Patients will be imme-
diately notiﬁed of their allocation through HOME BP
online, conﬁrmed by email or letter. Practice staff will
also be notiﬁed of patient group allocation by email.
Participants will be informed that the research team will
have access to their personal and study data to stay in
touch with them throughout the study.
Following randomisation, all patients will receive a BP
medication review with a trained HOME BP prescriber
(one or more GPs or nurse prescriber’s nominated by
the practice). For patients allocated to the intervention
group, prescribers will be asked to select and agree an
individualised medication titration plan (including three
potential medication changes should BP remain above
target). Participants allocated to usual care will receive a
routine hypertension medication review. None of the
study participants (patients or healthcare practitioners)
will be blinded to group allocation. At 6-months and
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12 months after randomisation, all patients will be
invited to a follow-up appointment with an independent
research nurse. This may take place within the clinic or
at a participant’s home. Patients will be asked to not
reveal their group allocation at this appointment, as
research nurses completing the 6-month and 12-month
follow-up appointments will be blinded to the patient’s
group. All follow-up BP measurements will be recorded
no earlier than 2 weeks before the follow-up date, and
no later than 4 weeks following the follow-up date at the
6-month follow-up. The follow-up period will be
extended up to a maximum of 8 weeks for the 12-month
follow-up. Patient BP readings and clinical measures will
be taken in the same way as baseline and follow-up ques-
tionnaires completed through HOME BP online.
Participant ﬂow through the trial is outlined in ﬁgure 1.
Participants will be withdrawn from the study if they
become no longer eligible to participate (eg, due to
pregnancy). Participants who choose not to continue
with the study will be offered the opportunity to con-
tinue self-monitoring only rather than withdrawing com-
pletely from the study, and asked if they would be
prepared to attend follow-up appointments.
Sample size consideration
A sample size of 244 patients per group is required in
order to have 90% power to detect a difference in SBP of
5 mmHg (SD 17 mmHg) between intervention and
control groups, based on the ﬁndings from the
TASMINH-2 study.20 Allowing for a 15% participant drop
out, we will seek to recruit 287 participants per condition,
resulting in a total sample size of 574 participants.
Recruitment
On the basis of our pilot work, and previous experience
from hypertension self-management interventions,21 we
estimate an approximate recruitment rate of 4% from
the practice invite mail-out. Assuming an average prac-
tice list size of 5000, with a prevalence of hypertension
of 13%, it is estimated that ∼75% of the hypertension
register will be excluded based on last BP reading and
other practice exclusions. We estimate that ∼15% of
patients invited will attend a baseline screening appoint-
ment, with ∼50% ineligible due to low BP readings
during the screening appointment. We also estimate that
a further 50% may decide not to participate due to the
online format of the intervention. Around 95 practices
are therefore likely to be required in order to recruit
the target number of participants (n=574).
HOME BP intervention
The HOME BP intervention consists of HOME BP
online (for patients and healthcare professionals), BP
self-monitoring, medication titration procedures and
optional behavioural support. Each of these components
is described below, guided by the TIDieR checklist
where possible.37 The intervention was developed using
a theory-based, evidence-based and person-based
approach,38 which is fully described elsewhere (article in
submission).
HOME BP online: patient behavioural components
HOME BP online will use behavioural techniques to
build patient motivation for BP self-monitoring, medica-
tion adherence and medication titration (Band R,
Bradbury K, Morton K, et al. Intervention planning for a
digital intervention for self-management of hyperten-
sion: a theory-, evidence- and person-based approach.
Implement Sci. In submission). This will include present-
ing the health-related beneﬁts of self-monitoring and
reducing BP through medication titration procedures.
Positive patient outcome expectancies will be encour-
aged by outlining ways that using the HOME BP inter-
vention may reduce the chances of experiencing
negative health consequences associated with hyperten-
sion. Common patient concerns regarding medication
side effects are also addressed.
Patients will be instructed how to correctly undertake
self-monitoring to promote patient self-efﬁcacy. An
Omron M3 monitor will be given to intervention group
participants, and training provided through HOME BP
online using a demonstration video. Participants will be
asked to rehearse self-monitoring for a minimum of
7 days and enter their practice readings into HOME BP
online before they are able to undertake study proce-
dures. Participants will be able to print off tables to
record each day’s readings off-line and then enter all
seven readings at one time (see ﬁgure 2 for screenshots
of the intervention pages). Patients will also be provided
with examples of successful hypertension management
using HOME BP procedures to further increase self-
efﬁcacy for BP management.
Nine weeks after participants have been allocated to
HOME BP, a behaviour change choice tool outlining the
speciﬁc beneﬁts of user-selected lifestyle modiﬁcations
targeting healthy eating, physical activity, losing weight
and salt and alcohol reduction will be available within
HOME BP online. Users will be have the option of
reading guidance about the beneﬁts and commitments
of each lifestyle change, so that they can choose the one
(or more) which would be best for them. Patients will be
reassured that additional behavioural support will be
provided by their practice HOME BP support provider
(usually a nurse or healthcare assistant) for self-
monitoring or lifestyle modiﬁcations, if required. The
rationale for providing these options 9 weeks after the
intervention began was to avoid making multiple behavi-
our changes39 until participants had an opportunity
to form habits around the key target behaviours of
self-monitoring and medication adherence.40
HOME BP online: healthcare practitioner behavioural
components
HOME BP online will build healthcare practitioner
motivation, knowledge, skills, positive outcome expecta-
tions and self-efﬁcacy for study procedures, particularly
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medication titration. Healthcare practitioner self-efﬁcacy
will be promoted by addressing concerns regarding
patient titration acceptance; the reliability of home
blood-pressure readings and study procedures as an
effective tool for overcoming clinical inertia for patients
and practitioners will be outlined. Evidence demonstrat-
ing the health-related beneﬁts of the medication
titration procedure will be presented, in addition to evi-
dence indicating that the medication escalation proce-
dures do not result in increased patient side
effects.14 20 21 Users will be provided with information
about the study procedures speciﬁc to their role (ie, pre-
scriber or support provider) and information relating to
study safety procedures.
Figure 1 Participant flow through the HOME BP study. GPs, general practitioners; HOME BP, Home and Online Management
and Evaluation of Blood Pressure.
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Figure 2 Screenshots of HOME
BP pages. HOME BP, Home and
Online Management and
Evaluation of Blood Pressure.
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Patients and healthcare practitioners will be able to
re-access their speciﬁc behavioural intervention compo-
nents from HOME BP online at any time throughout
the study.
Self-monitoring procedures
Patients will be advised to take two morning BP readings
for 7 days each month and in each case to use the
second reading (as per the TASMINH2 and TASMIN-SR
studies).20 21 Automated email prompts will be sent to
participants as reminders to begin BP self-monitoring.
Patients will need to have seven readings to enter into
HOME BP online, but will be able to ﬂexibly complete
their readings over a 2-week period if required.
Following the completion of each set of seven readings,
patients will have access to the behavioural intervention
components described above, but will not enter further
BP readings for further 4 weeks.
BP targets
BP targets will be set in line with the National Institute
for Health and Care Excellence (NICE) hypertension
guidelines,41 with adjustment by 5/5 mmHg for home
readings.42 People under 80 without diabetes will have BP
targets of <135/85 mmHg, while patients aged 80 and
over without diabetes will have a target BP of <145/
85 mmHg. Target BP for all patients with diabetes will be
<135/75 mmHg (those with proteinuria and therefore
lower targets are excluded). After the seven readings are
entered in to HOME BP online, the mean BP will be cal-
culated and feedback provided to the patient and the
healthcare practitioners according to a trafﬁc light system
(developed from that used in previous medication titra-
tion procedures).20 21 These readings will be used to
inform the medication titration procedure.
Medication titration procedures
All HOME BP prescribers will receive a copy of the NICE
hypertension guidelines41 and will complete an individua-
lised patient medication review at baseline for interven-
tion group participants, where three potential medication
changes will be selected and agreed with the patient. If a
patient’s mean BP readings are above target for two con-
secutive months, the medication titration procedure will
be initiated by HOME BP online. Patients and practice
staff will be informed by email that a medication change
is recommended. The prescriber will be asked to imple-
ment the preplanned medication change and conﬁrm
this with the patient (or explain the reasons for non-
implementation, if applicable). If patients decide not to
initiate a medication change, the prescriber will receive
information provided by the patient outlining the reasons
for non-titration. When a recommended medication
change is not initiated, an above target reading at the
subsequent BP entry will again prompt a medication
change recommendation from HOME BP online.
If patients take two BP readings that are too high
(>180/110 mm Hg) or low (SBP <100 mm Hg), they will
be asked to repeat the measurement after 5 min. If read-
ings are still too high or too low, the HOME BP health-
care practitioners will be alerted by email and patients
will be advised to make an appointment with the pre-
scriber in the usual way within 3 days. Decisions about
patients’ medication will remain at the prescriber’s dis-
cretion at all times. If a mean target BP (ie, below target
but SBP above 100 mm Hg) is entered into HOME BP
online for three consecutive months, patients will be
advised to reduce BP monitoring to once every 8 weeks
as their BP is currently well controlled. This will revert
to monthly should subsequent mean BP rise above
target.
HOME BP behavioural support
Optional additional behavioural support for self-
monitoring and lifestyle modiﬁcations will be available
to all patients via the practice support providers, who
will be trained in applying the CARE (Congratulate, Ask,
Reassure, Encourage) approach (paper outlining this
approach in HOME BP forthcoming). A face-to-face
appointment is offered to all participants at 4 weeks fol-
lowing randomisation and 1 week after any lifestyle mod-
iﬁcations are introduced, with an option for remote
telephone or email support if preferred. A maximum of
six face-to-face support sessions will be available if
patients experience difﬁculties associated with self-
monitoring or lifestyle change, and patients will have
the option to email their support provider through
HOME BP online at any point. Template-guided motivat-
ing and reassuring support messages will be sent by
email from the support provider to all patients every
4 weeks to encourage and reinforce patient adherence
to monitoring, medication regimes and lifestyle changes
(where applicable).
Monitoring adherence
Automated email reminders will be sent to patients and
healthcare practitioners at key milestones to promote
adherence to study procedures. Adherence to titration
procedures will also be monitored by the healthcare
practitioners and study team to ensure changes have
been enacted (or to understand why not). At the end of
the study, each HOME BP supporter will return a copy
of their support log. An audit of a selection of BP moni-
tors will be conducted.
Usual care
Patients allocated to usual care will have access to the
information provided in the Blood Pressure UK patient
leaﬂet for hypertension through HOME BP online.
They will receive routine hypertension care, with
appointments and medication changes made at the GP’s
discretion.
Outcomes
The primary outcome of the trial will be difference in
ofﬁce SBP (mm Hg, mean of second/third readings) at
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12-month follow-up between the intervention and
control groups adjusting for baseline BP, practice, BP
target levels and gender. These will be entered and
stored on an independent, secure server.
Secondary outcomes (also adjusted for baseline and cov-
ariates where appropriate) will comprise:
▸ Difference in ofﬁce SBP between intervention and
control groups at 6-month follow-up.
▸ Difference in ofﬁce DBP between intervention and
control groups at 6-month and 12-month follow-up.
▸ Difference in ofﬁce SBP and DBP at 6 and 12 months
using the mean of the second to sixth BP readings.
▸ Difference in health-related quality of life measured
using EQ-5D-5L.43
▸ Difference in patient enablement measured using the
patient enablement instrument.44
▸ Economic modelling (including cost of equipment
and drugs, patient and healthcare professional time
and support provision).
Process evaluation measures will include:
▸ Medication beliefs measured using the Beliefs about
Medicines Questionnaire (BMQ)45 and medication
adherence using the Medication Adherence Report
Scale (MARS).46
▸ Patient perceived side effects measured using the
symptom subscale of the Illness Perception question-
naire (IPQ-R) hypertension.47
▸ Patient self-efﬁcacy.48
▸ Medication use (number and deﬁned daily doses).49
▸ Patient weight measured within clinic and self-
reported lifestyle behaviours.
▸ Prescriber and support provider self-efﬁcacy and
outcome expectations.
▸ Prescriber and support provider conﬁdence in the
acceptability of the intervention.
Intervention group only:
▸ DI website usage and engagement, including lifestyle
choice, usage and progress.
▸ Patient BP monitoring adherence measured by the
HOME BP online system.
▸ Adherence to recommended medication changes.
▸ Usage of optional support provision.
▸ Prescriber initiation of titration procedures.
Adverse events
HOME BP healthcare practitioners will inform investiga-
tors of all patient adverse events occurring throughout
the trial. The assessment of whether or not an serious
adverse event (SAE) is an expected consequence of
receiving the intervention will be provided by the chief
investigator (or clinical reviewer delegate), it will not be
provided by the investigator responsible for the care of
the participant.
Study end points
Participants in the intervention and control groups will
be invited to appointments with an independent
research nurse for assessment of primary and secondary
end points at 6 months and 12 months following entry
into the study. These appointments will be conducted in
the same way for both groups. Any other contacts with
the GP practice (outside of the study) will be recorded
in the medical notes and reported for the economic
analysis at the end of the trial (based on blind review of
patient medical notes). Only members of the study
research team involved in the data collection, and data
analysis will have access to the ﬁnal trial data set.
Measures
See table 1 for full details of study measures.
Statistical analysis
The principal analysis will use raw and adjusted data and
will be performed at the end of the trial after all data
have been collected. The primary analysis will use
general linear modelling to compare intervention and
usual care SBP at follow-up adjusting for baseline BP,
practice (as a random effect), BP target levels and
gender. Analyses will be on an intention to treat basis
with imputation. Secondary analyses will be reported for
complete cases. No interim analyses will be performed.
A sensitivity analysis will examine the potential effect of
missing data using multiple imputation. Planned sub-
group analyses will be of BP target groups, older versus
younger (65 as threshold), men versus women and
better controlled at baseline versus worse controlled at
baseline (median SBP). Secondary analyses will use
similar techniques to assess differences between groups
in SBP at 6 months, DBP at 6 months and 12 months,
medication use and quality of life. Additional analyses
will examine patient and healthcare professional adher-
ence to advice and study processes, website usage and
support provision. Process analyses will be reported else-
where, but will assess the impact of patient enablement
and self-efﬁcacy, symptom perceptions and medication
beliefs on outcomes. These analyses will also examine
the relationship between support uptake, engagement
with healthy behaviour change and outcomes.
Economic analysis
TASMINH220 resulted in a 5.4 mm Hg reduction in BP
in self-management compared with usual care which was
cost-effective with £1.6k per QALY for men and £4.9k
for women. Thus if HOME BP results in the hypothe-
sised difference of 5 mm Hg, then using the same
cost-effectiveness model, it will be highly cost-effective—
unless of course the costs are much greater. The inter-
vention cost in TASMINH2 was £105, which included
the BP monitor, tele-monitoring connection and train-
ing costs (see table 2 in Kaambwa et al50). Key differ-
ences between the interventions in HOME BP and
TASMINH2 have to do with the use of behavioural tech-
niques in the former, including guidance about lifestyle
change and support in making such changes as well as
recommendations to change medications with recording
of whether such changes were made and further
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Table 1 Measures and schedule of observations within the HOME BP trial
Time point
Measure Baseline/screening Visit 1 Visit 2 Intervention group only Usual care group only
Month 0 6 12 (0–12) 12
Patient sociodemographic measures X
Frequency of previous self-monitoring X X
Clinical measures
Systolic BP (SBP) X X X
Diastolic BP (DBP) X X X
Weight (kg) X X
Height (cm) X
Diabetes status X
Hypoglycaemic episodes in last 6 months X X X
Medication changes (prescriptions issued) X (NR)
Consultations X (NR)
Patient self-report measures
Patient enablement instrument X X
Patient self-efficacy X X X
Beliefs about medication (BMQ) X X X
Medication adherence (MARS) X X
Patient perceived side effects (IPQ-R hypertension: symptoms subscale) X X
Changes to lifestyle behaviours X
Patient objectively recorded measures
Website usage X*
Usage of hypertension pages X*
Monitoring of blood pressure
Self-reported SBP X*
Self-reported DBP X*
Medication titration recommended X*
Titration uptake X*
Reasons for non-titration X*
Usage of lifestyle pages X*
Choice of lifestyle changes X*
Reported progress on lifestyle change (eg, weight change) X*
HCP objectively recorded measures
Usage of training pages (prescriber guide) X
Emails sent to the patient X
Titration procedure compliance X
Support provision X
HCP self-report measures
Self-efficacy and outcome expectations X†
Confidence in the acceptability of the intervention (for patients) X†
Continued
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reminders if not. HOME BP thus tests the intervention
as delivered digitally and the additional value of behav-
ioural support in self-management. To facilitate costing
of the behavioural add-ons to self-management, the
costing of the intervention in HOME BP as far as pos-
sible will separate these elements.
Economic analysis plan
A within trial analysis will estimate cost per unit reduc-
tion in SBP, the primary outcome, with adjustments in
that outcome as described in the ‘Statistical analysis’
section, including subgroups. Costs will include those
due to the intervention, as well as those due to changes
in medication, use of other relevant NHS resources and
any costs borne by patients such as in diet and lifestyle.
NHS and societal costs will be estimated and uncertainty
explored in sensitivity analyses. To facilitate analysis of
the difference between the intervention in HOME BP
and that of self-management, the components and the
cost of the intervention in HOME BP will be compared
with that of TASMINH2.
These short-term results will provide input to a long-
term cost-effectiveness model, based on that developed
for TASMINH2, updated by subsequent work as relevant.
Since these studies all show reductions in BP as cost
reducing or highly cost-effective, this modelling will
address the cost-effectiveness of the HOME
BP-intervention versus usual care but also of the add-
ition of the behavioural/digital element relative to
paper-based self-management without that element. The
HOME BP trial will collect data on numbers and types
of antihypertensive prescriptions between arms.
Qualitative substudy
The qualitative interviews will seek to provide an
in-depth understanding of the factors that may facilitate
or diminish the acceptability of the HOME BP interven-
tion, and adherence to implementation from the per-
spective of patients and healthcare professionals using
HOME BP. Interviews and focus groups will be under-
taken alongside participation and after participants
ﬁnish the HOME BP intervention for patients in the
intervention and usual care groups. Purposive sampling
will be used to select patients from the intervention
group by age, gender, socioeconomic status and level of
engagement with the website to allow for a wide range
of views and experiences of the HOME BP online and
the HOME BP intervention. Open-ended inductive
questions will be used to elicit user perspectives and
experiences of the intervention and the support pro-
vided, allowing participants to freely describe their
experiences and views in their own way and to focus on
whatever is most salient to them. Focus group discus-
sions and interviews will also be conducted with health-
care professionals who have been involved in the trial
procedures or intervention delivery. Interviews and focus
groups will be audio-recorded, fully transcribed and ana-
lysed thematically.
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ETHICS AND DISSEMINATION
Ethical approval
Ethical approval for the HOME BP study has been
obtained from the South Central—Hampshire A Ethics
Committee (reference: 15/SC/0082). R&D approvals
have been obtained from all relevant Clinical Research
Networks. All substantial amendments must be approved
by the University Ethics Committee and NHS Ethics
Committee responsible for the trial, in addition to
approval by NHS R&D. Investigators are kept up to date
with relevant changes via regular management group
meetings.
Data monitoring
The Programme Steering Committee is responsible for
ensuring programme adherence to the protocol, and
adherence to the requirements of the Guidelines for
Good Clinical Practice. It was decided by the Steering
Committee that a data monitoring committee was not
required. The trial may be subject to inspection and
audit by University of Southampton, under their remit
as sponsor, the trial coordinating centre as the Sponsor’s
delegate and other regulatory bodies.
Dissemination
Dissemination of our research will be via multiple path-
ways. We will submit the primary, secondary and tertiary
study results for publication in highly cited and open
access peer-reviewed journals and present ﬁndings at
national and international conferences. We will also
provide summaries of HOME BP ﬁndings to professional
societies (such as British Hypertension Society), patient
groups (Blood Pressure UK), participants, NHS organi-
sations and healthcare providers. We will also dissemin-
ate to the public through regular press releases and to
stakeholders through interactive workshops.
If cost-effective, the HOME BP intervention will be dis-
seminated for clinical use by University of Southampton
or a suitable, appropriate licensed partner. Following the
Behavioral Intervention Technology model,51 we antici-
pate that future technology enhancements in mode of
delivery of the intervention will be possible and desir-
able without the need to re-evaluate the essential behav-
iour support content of the intervention. For example,
as smartphone use becomes more prevalent in the
target population it will be easy to transfer the content
of HOME BP for delivery by smartphone, with automatic
transfer of BP readings (which will reduce the potential
for patient error).
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